Brain tumour clinical trial title

CRUKD/11/006: OPARATIC A Cancer Research UK Trial of olaparib (AZD2281), an oral PARP inhibitor, combined with extended low-dose oral temozolomide in patients with relapsed glioblastoma

Brain tumour type




Interventional: drug. Glioblastoma multiforme (GBM) is the commonest and most aggressive primary brain tumour. Most tumours are resistant to current treatment. AZD2281 is an oral, potent inhibitor that increases the sensitivity of human glioma cells to radiation and temozolomide. Phase 1 studies demonstrate effective PARP inhibition in tumour tissue at non toxic doses. The aims of this phase 1 study of AZD2281 in combination with extended daily low-dose temozolomide in patients with recurrent GBM is to established the optimum biological dose of AZD2281 and the maximum tolerated dose of temozolmide in combination. 


Date added:

Open/Closed: Open

Trial ends: May 2016


Beatson West of Scotland Cancer Centre

Contact details

Professor Anthony Chalmers : Chair of Clinical Oncology
1053 Great Western Road
Western Road
G12 0YN
Telephone: 0141 301 7097

Find on Google maps »